Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/18/2025

Escitalopram Tapering Plan for Pregnant Patients

Rationale for Continuation vs. Tapering

  • The American Academy of Pediatrics recommends maintaining SSRI treatment during pregnancy at the lowest effective dose because withdrawal of medication may have harmful effects on the mother-infant dyad, and untreated depression during pregnancy carries significant risks including premature birth and decreased breastfeeding initiation 1
  • Opioid withdrawal principles do not apply to SSRIs in pregnancy, as SSRI discontinuation primarily risks maternal depression relapse rather than acute withdrawal-related pregnancy complications, and multiple reviews have not identified adverse neurodevelopmental outcomes among infants born to women treated with SSRIs during pregnancy 1
  • Sertraline, a related SSRI, has a well-established safety profile during pregnancy with a number needed to harm of 286-351 for persistent pulmonary hypertension of the newborn 1
  • The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, notes that opioid withdrawal is associated with spontaneous abortion and premature labor, which is not the case with SSRIs 2

Monitoring and Tapering

  • Monitor for withdrawal symptoms, including anxiety, insomnia, irritability, dizziness, nausea, and headache, and pause the taper if withdrawal symptoms emerge and restart when the patient is ready 2
  • Slow the taper further once reaching low doses, and reduce the dose by approximately 10% of the current dose per month, as slower tapers are better tolerated for patients on medications long-term 2

Neonatal Considerations

  • Neonates exposed to escitalopram late in third trimester may develop transient complications, including crying, irritability, tremors, poor feeding, hypertonia, tachypnea, sleep disturbance, hypoglycemia, and rarely seizures, which typically resolve within 1-4 weeks and are generally mild 1
  • Arrange early follow-up after delivery, as infants are at risk for withdrawal or toxicity symptoms over the first week of life, and inform the pediatric team about maternal escitalopram use so they can anticipate and manage neonatal adaptation syndrome 1

Discontinuation

  • Do not discontinue abruptly without a gradual taper if discontinuation is necessary, as recommended by the Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports 2

REFERENCES

1

Management of Sertraline During Pregnancy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026